Natera, One Lambda partner to co-distribute kidney transplant rejection test

Parisa Khosropour
Parisa Khosropour

Natera Inc. has announced a partnership with Thermo Fisher Scientific’s One Lambda brand to co-distribute Natera’s kidney transplant rejection test in the United States, according to a press release from Natera.

“Natera’s donor-derived cell-free DNA test complements our existing transplant offerings and enables us to provide a more advanced portfolio for monitoring kidney rejection,” Parisa Khosropour, president of transplant diagnostics at Thermo Fisher Scientific, said in the release.

Designed to detect active allograft rejection in patients who have had a kidney transplant, Natera’s organ transplant rejection assay measures the fraction of donor-derived cell-free DNA in the blood and detects acute rejection with 89% sensitivity, according to the release.

Steve Chapman
Steve Chapman

“We are excited to partner with One Lambda, a pioneer in transplant diagnostics,” Steve Chapman, CEO of Natera, said in the release. “This partnership will help accelerate our entry into this new market by leveraging the commercial infrastructure of a highly respected and well-established leader in the field, along with our direct sales team.”

Reference: https://www.natera.com/press-releases/natera-announces-agreement-one-lambda-co-distribute-its-kidney-transplant-rejection

 

 

 

 

 

 

 

 

 

 

Parisa Khosropour
Parisa Khosropour

Natera Inc. has announced a partnership with Thermo Fisher Scientific’s One Lambda brand to co-distribute Natera’s kidney transplant rejection test in the United States, according to a press release from Natera.

“Natera’s donor-derived cell-free DNA test complements our existing transplant offerings and enables us to provide a more advanced portfolio for monitoring kidney rejection,” Parisa Khosropour, president of transplant diagnostics at Thermo Fisher Scientific, said in the release.

Designed to detect active allograft rejection in patients who have had a kidney transplant, Natera’s organ transplant rejection assay measures the fraction of donor-derived cell-free DNA in the blood and detects acute rejection with 89% sensitivity, according to the release.

Steve Chapman
Steve Chapman

“We are excited to partner with One Lambda, a pioneer in transplant diagnostics,” Steve Chapman, CEO of Natera, said in the release. “This partnership will help accelerate our entry into this new market by leveraging the commercial infrastructure of a highly respected and well-established leader in the field, along with our direct sales team.”

Reference: https://www.natera.com/press-releases/natera-announces-agreement-one-lambda-co-distribute-its-kidney-transplant-rejection